JeanMichel Halfon - Teva Pharma Statutory - independent director
| TEVA Stock | USD 16.61 0.17 1.01% |
Director
Mr. JeanMichel Halfon is Independent Director of the Company. Mr. Halfon joined the Board of Directors in 2014. He currently serves as an independent consultant, providing consulting services to pharmaceutical, distribution, healthcare IT and RD companies. From 2008 to 2010, Mr. Halfon served as President and General Manager of Emerging Markets at Pfizer Inc., after serving in various senior management positions since 1989. From 1987 to 1989, Mr. Halfon served as Director of Marketing in France for Merck Co., Inc since 2014.
| Age | 68 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 124 Dvora HaNevi?a St., Tel Aviv, Israel, 6944020 |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0509 % which means that it generated a profit of $0.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.283) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.08. The current year's Return On Capital Employed is expected to grow to -0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.3 B, whereas Total Assets are forecasted to decline to about 26.8 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Costa Saroukos | Takeda Pharmaceutical Co | 49 | |
| William Steere | Zoetis Inc | 83 | |
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| David Ricks | Elanco Animal Health | 52 | |
| Koji Hatsukawa | Takeda Pharmaceutical Co | 68 | |
| Norma Beauchamp | Aurora Cannabis | 59 | |
| William Doyle | Elanco Animal Health | 58 | |
| Kirk McDonald | Elanco Animal Health | 54 | |
| Michael Harrington | Elanco Animal Health | 58 | |
| Sanjay Khosla | Zoetis Inc | 68 | |
| Joshua Smiley | Elanco Animal Health | 50 | |
| JeanLuc Butel | Takeda Pharmaceutical Co | 64 | |
| Frank DAmelio | Zoetis Inc | 63 | |
| Art Garcia | Elanco Animal Health | 59 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| John Bilbrey | Elanco Animal Health | 64 | |
| David Lazzarato | Canopy Growth Corp | 64 | |
| Jason Dyck | Aurora Cannabis | N/A | |
| Willie Reed | Zoetis Inc | 65 | |
| Tyler Burns | Canopy Growth Corp | N/A | |
| Linda Rhodes | Zoetis Inc | 70 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | 0.0509 |
Teva Pharma Industries Leadership Team
Elected by the shareholders, the Teva Pharma's board of directors comprises two types of representatives: Teva Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharma's management team and ensure that shareholders' interests are well served. Teva Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Matthew Shields, Executive Operations | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Janet Vergis, Independent Director | ||
| Amir Weiss, Senior Vice President Chief Accounting Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Richard Francis, CEO President | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Christopher CFA, Senior Intelligence | ||
| Galia Inbar, Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | ||
| Eli Shani, Executive Vice President - Global Marketing and Portfolio | ||
| Abbas Hussain, Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Vikki Conway, Acting Resources | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Advocate Baron, Senior Auditor | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President | ||
| Kathleen Veit, Global President | ||
| Ran Meir, Head Relations | ||
| David JD, Executive Officer | ||
| Perry Nisen, Independent Director | ||
| Placid Jover, Executive CHRO | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Tal Zaks, Independent Director | ||
| Kevin Mannix, Head of Global Investor Relations and VP | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Andrew Weil, Chief Accounting Officer | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | ||
| Dov Bergwerk, Acting Secretary | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | 0.0509 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 33.75 B | ||||
| Shares Outstanding | 1.15 B | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 60.11 % | ||||
| Number Of Shares Shorted | 22.36 M | ||||
| Price To Earning | 15.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.